Many new therapeutics for Alzheimer's disease delay the accumulation of amyloid-β (Aβ) in
transgenic mice, but evidence for clearance of preexisting plaques is often lacking. Here, we …

The role of microglia in the removal of amyloid deposits after systemically administered anti-
Aβ antibodies remains unclear. In the current study, we injected Tg2576 APP transgenic …

Although anti-human β-amyloid (Aβ) immunotherapy clears brain β-amyloid plaques in
Alzheimer's disease (AD), targeting additional brain plaque constituents to promote …

Alzheimer's disease is a major health problem with limited available medical treatment
options. Immunotherapy is one approach with the potential to slow or reverse the disease …

Amyloid-β (Aβ) accumulation in senile plaques is a hallmark of Alzheimer's disease (AD).
Immunotherapy is a leading approach for amyloid clearance, despite the early termination of …

The mechanisms by which anti-Aβ antibodies clear amyloid plaques in Aβ depositing
transgenic mice are unclear. In the current study, we demonstrate that inhibition of anti-Aβ …

Amyloid-beta (Aβ) is suggested to play a causal role in the pathogenesis of Alzheimer's
disease (AD). Immunotherapies are among the most promising Aβ-targeting therapeutic …

The induction of an antibody response to amyloid beta (Aβ) peptide has become a strategy
for the treatment of Alzheimer's disease (AD). This has proven effective in reducing the …

Immunotherapy can attenuate amyloid neuropathology and improve cognitive function in
transgenic models of Alzheimer's disease. However, the first clinical trial was halted when …

After many years of intense research on the etiology and pathogenesis of Alzheimer's
disease (AD), the amyloid β (Aβ) peptide, the major component of senile plaques, has …